19:10 , Mar 9, 2018 |  BC Week In Review  |  Company News

Aridis, Shenzhen Hepalink form China JV

Aridis Pharmaceuticals Inc. (San Jose, Calif.) and Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) formed a JV -- Shenzhen Arimab Biopharmaceuticals Co. Ltd. -- to develop and gain regulatory approval of two of Aridis’ candidates, Salvecin...
07:00 , May 27, 2013 |  BC Week In Review  |  Company News

Aridis, Kenta deal

Aridis Pharmaceuticals LLC, San Jose, Calif.   Kenta Biotech Ltd., Schlieren, Switzerland   Business: Infectious   Infectious disease company Aridis will acquire Kenta's portfolio of six anti-infective human mAbs and technologies for an undisclosed cash amount. The assets...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Clinical News

Panobacumab: Additional Phase IIa data

Data from 13 patients who received 3 doses of panobacumab in an open-label, European Phase IIa trial showed that the 30-day mortality rate was 0%, which Kenta said compared favorably to the mortality rate of...
07:00 , Sep 21, 2009 |  BC Week In Review  |  Clinical News

Panobacumab: Phase IIa data

Data from an open-label, European Phase IIa trial in 13 evaluable patients showed that panobacumab resulted in a 28-day mortality rate of 7% compared to 25.6% as predicted by the acute physiology and chronic health...
00:38 , Mar 13, 2009 |  BC Extra  |  Financial News

Kenta raises $10.3 million

Kenta (Berne, Switzerland) raised CHF12 million ($10.3 million) in a series B round. Existing investors Ingro Finanz; Varuma; and Regos participated. Kenta's lead compound is KBPA101, a human IgM mAb against Pseudomonas aeruginosa in...
08:00 , Jan 29, 2007 |  BioCentury  |  Product Development

Ophthalmic reprofilers

Ophthalmic reprofilers Ophthalmic reprofilers For a number of companies in the ophthalmic space, an important component of their strategy is to take compounds that have been developed for other indications and reprofile them with an...
07:00 , Oct 9, 2006 |  BC Week In Review  |  Clinical News

KBPA101 regulatory update

FDA granted Orphan Drug designation for KBPA101 to treat pneumonia caused by Pseudomonas aeruginosa serotype O11. The human monoclonal antibody against P. aeruginosa also has Orphan Drug designation in Europe. Kenta Biotech Ltd., Berne, Switzerland...
07:00 , Jul 31, 2006 |  BC Week In Review  |  Clinical News

KBPA101 regulatory update

The EC granted Orphan Drug designation to KBPA101 to treat pneumonia caused by serotype O11 Pseudomonas aeruginosa. The human monoclonal antibody against P. aeruginosa is in Phase II testing. Kenta Biotech Ltd., Berne, Switzerland   Product:...
07:00 , Oct 17, 2005 |  BioCentury  |  Finance

Ebb & Flow

Germany's Jerinihas been tipped as a potential European IPO for more than a year, but the company has always maintained that it would go when the climate was right. The company has decided that now...
00:05 , Oct 13, 2005 |  BC Extra  |  Financial News

Aerie raises $21 million

Ophthalmic company Aerie ( Research Triangle Park, N.C.) raised $21 million in a series A round led by Alta Partners and Texas Pacific Group. Texas Pacific's Geoff Duyk and Alta's David Mack will join Aerie's...